[Evaluation of reactivity and immunogenicity of a cultured concentrated inactivated vaccine against hepatitis A "Hep-A-In-Vak"].
Clinical trials of inactivated hepatitis A vaccine Hep-A-in-Vac demonstrated its specific safety and moderate reactogenicity, manifesting by short-term fibrillar twitching of musculus deltoideus at the site of injection. After a course of three immunizations 87.5% seronegative vaccines developed a high level of specific antibodies to hepatitis A virus with at least 100 reverse values of titers. In controls antibody titers remained seronegative in 90% cases. These data indicate evident immunologic activity of Hep-A-in-Vac vaccine.
Gorbunov
M A
MA
Pavlova
L I
LI
Karpovich
L G
LG
Kalashnikova
T V
TV
Bektimirov
T A
TA
Levina
V D
VD
Maĭdaniuk
A G
AG
Ermolaeva
T N
TN
Shervarli
V I
VI
Balashev
B P
BP
D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis; D006506:Hepatitis A / Q000276:immunology* / Q000517:prevention & control; D006507:Hepatovirus / Q000276:immunology*; D006801:Humans; D014765:Viral Vaccines / Q000096:biosynthesis / Q000276:immunology*
D000914:Antibodies, Viral; D014765:Viral Vaccines
Otsenka reaktogennosti i immunogennosti kul'tural'noĭ kontsentrirovannoĭ inaktivirovannoĭ vaktsiny protiv gepatita A "Gep-A-In-Vak".